QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • CytRx Corp. (CYTR) Continues To Build Oncology Portfolio, Headed By Lead Candidate Aldoxorubicin 0 comments
    Oct 25, 2013 3:17 PM | about stocks: CYTR

    CytRx is a biopharmaceutical research and development company with a particular focus on expanding its pipeline of oncology candidates in various stages of preclinical and clinical development.

    Aldoxorubicin is the company's novel version of the commonly prescribed chemotherapeutic agent doxorubicin, which is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. Aldoxorubicin differs in that it has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which the company believes could lead to improved efficacy.

    CytRx holds the exclusive worldwide rights to aldoxorubicin. The candidate has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer.

    CytRx recently announced favorable results from its phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors, and has initiated a phase 2b international clinical trial in patients with soft tissue sarcomas, and a phase 2 clinical trial in patients with pancreatic cancer.

    The company in December plans to report top-line phase 2b data, which the company anticipates will provide the first direct clinical trial comparison of aldoxorubicin with native doxorubicin as a first-line treatment for soft tissue sarcoma.

    CytRx also has rights to two additional drug candidates: tamibarotene, for which the company has completed evaluation in the ENABLE Phase 2 clinical trial in lymphocytic leukemia and for which it plans to seek a partnership for further development; and befetinib, which the company is evaluating for further development.

    For more information visit cytrx.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: CYTR
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.